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Background: Sleep-disordered breathing (SDB) in patients with heart failure (HF) is of major prognostic 
impact, though treatment of simultaneously occurring central and mixed apnea events is chall enging.
The objective was to examine long-term effects of a new trilevel adaptive servoventilation (ASV) therapy 
in patien ts with systolic or diastolic HF.
Methods : A total of 45 consecutive patients with a history of HF, elevated N-termina l prohormone of
brain natriuretic peptide levels, objective signs of cardiac dysfunction, and modera te to severe SDB 
(apnea-hypopnea index [AHI] P15/h) with combined central and mixed respiratory events were 
included in this study and ASV therapy (SOMNOvent CR, Weinmann) was offered.
Results: In 38 patients (84%), ASV therapy was successfully initiated, with 23 (51%) patients showing 
appropriate compliance (device use P4 h/night for P5 d/w) after 3.6 ± 1.2 months. In these patients 
ASV therapy and HF status were re-evaluated. A sustained reduction was achieved in AHI (42.8 ± 17.5/ 
h vs 8.9 ± 5.8/h; p < 0.001) and oxygen saturation. Improvements also were recorded in New York Heart 
Associa tion (NYHA) functional class (2.4 ± 0.5–1.9 ± 0.4; p < 0.001) and oxygen uptake during cardiopul- 
monary exercise testing (VO2 peak, 13.64 ± 3.5–15.8 ± 5.8 ml/kg/min; p < 0.002).
Conclusion: In selected HF patients, trilevel ASV therapy is able to treat SDB with combined central and 
mixed respiratory events. This treatment is associated with an improvement in HF symptoms and objec- 
tive cardiopulmonary performance.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction 
A remarkabl y high prevalen ce of sleep-disorder ed breathing 
(SDB) has been observed in heart failure (HF) patients. Indepen- 
dent of the type of underlying cardiac disease, systolic or diastolic 
dysfunction , large scale studies revealed a prevalen ce of SDB be- 
tween 69% and 76% [1,2]. Central sleep apnea with Cheyne–Stokes
respiration (CSR) is characterized by recurrent central apneas alter- 
nating with a crescendo–decrescendo pattern of tidal volume [3,4].
CSR often is observed in non-REM sleep stages 1 and 2 and is asso- 
ciated with hyperventilation, apnea-related oxygen desaturation s,
increased sympatheti c nerve activity, circulatory delay, and re- 
duced blood gas buffering capacity [5–9]. In HF patients, SDB in
general and CSR in particular are supposed to be associated with 
increased mortality [10,11].y, Heart and Diabetes Centre 
eorgstrasse 11, D-32545 Bad 
+49 5731 97 2194.
burg).
-NC-ND license.Although initial results with continuous positive airway pres- 
sure (CPAP) therapy to treat CSR were promising [12], the subse- 
quent CANPAP (CANadian continuous Positive Airway Pressure)
trial failed to show a positive impact on mortality in CPAP-tre ated 
HF patients with CSR [13]. Despite an improvem ent in nocturnal 
oxygenati on, lowered norepinephrine plasma levels, and better 
performanc e in six-minute walking tests, mortality was not im- 
proved [13]. A later post hoc analysis of this trial demonstrated a
beneﬁt to transplant-free survival in patients with effective sup- 
pression of respiratory events with CPAP therapy [14].
Adaptive servoventilatio n (ASV) therapy is the latest method of
ventilator support, specially designed to treat CSR in HF patients.
ASV restabilizes CSR by applying anticyclic pressure support in
phases of cyclic breathing [15]. The acute effects of different ther- 
apeutic options including oxygen, CPAP, bilevel, and ASV were 
compare d in a one-night study of HF patients with CSR. All types 
of treatment were able to reduce central events and arousal activ- 
ity to some degree but ASV was most effective [16,17]. The superi- 
ority of ASV to CPAP in reducing the apnea-hypo pnea index (AHI)
in Cheyne–Stokes breathing was veriﬁed in further clinical studies 
[18,20].
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device on respiratory and cardiac parameters in a cohort of pa- 
tients with systolic or diastolic HF and nocturnal CSR with concom- 
itant mixed apneic events.
2. Methods 
2.1. Patients 
From 03/2009 to 12/2010 a total of 45 patients with HF caused 
by systolic or diastolic dysfunct ion and moderate to severe SDB 
with central and mixed sleep apnea were consecut ively included 
in our study. All patients were referred to the Heart and Diabetes 
Center North Rhine Westphalia for diagnosis and treatment of
SDB. Diagnosis of HF was based on typical clinical signs and symp- 
toms of HF (New York Heart Associati on [NYHA] functional 
classP II, elevated N-terminal prohormone of brain natriuretic 
peptide concentr ations), with either reduced left ventricul ar ejec- 
tion fraction (LVEF)( 6 45%) or with diastolic dysfunction as speci- 
ﬁed by European Society of Cardiology guidelines [21,22]. The 
study was approved by our local ethics committee.
2.2. Polysomnogra phy 
Overnight in hospital–attended polysomnogr aphy (PSG)
according to the 2007 guidelines of the American Academy of Sleep 
Medicine was performed during a diagnostic night, as well as dur- 
ing ASV therapy initiation and follow-up [23]. PSG recordings 
including arousal analyses were independen tly analyzed (T.F.,
C.E.). For study enrollment, a patient’s PSG recordings had to reveal 
a moderate to severe SDB (AHIP 15/h) with a majority of central 
and mixed apneic events and less than 20% of events scored as
being obstructi ve.
2.3. Trilevel adaptive servoventilati on
Trilevel adaptive servoventi lation (SOMNOvent CR, Weinmann,
Hamburg, Germany ) uses three different pressure levels over the 
course of the breathing cycle (Fig. 1). The inspirato ry positive air- 
way pressure (IPAP) pressure provides the inspiratory splint and 
ventilation. Maximal IPAP can be increased up to 20-hour Pa. Expi- 
ratory pressure is varied between a lower level at the start of expi- 
ration expiratory positive airway pressure and a higher level at the Fig. 1. Trilevel ASV uses three different pressure levels over the course of the breath
inspiratory splint and ventilation. Maximal IPAP can be increased up to 20-hour Pa. Expir
higher level at the end of expiration (EEPAP).end of expiration end-expi ratory positive airway pressure . The reg- 
ulation of the device is based on ﬂow, pressure, and snoring sig- 
nals. For each breath, current minute ventilatio n is measured and 
compare d to the patient’s average respirato ry minute ventilatio n.
The algorithm is aimed at damping the respiratory instability in
CSR and restoring stable breathing.
2.4. ASV therapy initiation 
PSG recordings were explained to each patient individua lly and 
ASV treatment was offered to every patient. Mask ﬁtting and ASV 
testing were done in the afternoon and included blood pressure,
heart rate and leakage monitoring and close clinical observations .
In patients consenting to further treatment, ASV was individually 
titrated during the following night with PSG surveillance. The next 
morning PSG results were analyzed independen tly (T.F.) and long- 
term treatment was initiated if patients agreed to further treat- 
ment and AHI was 610/h or 650% of baseline.
2.5. Follow-up 
Follow-up was schedule d three months later and included over- 
night PSG on ASV treatment, compliance check based on device 
stored data, clinical examination , vital signs, capillary blood gas 
analysis and cardiopul monary exercise testing. Appropriate com- 
pliance/a dherence to therapy was deﬁned as using the device 
Pfour hours per night for Pﬁve days a week.
2.6. Cardiopu lmonary exercise testing 
Symptom-lim ited bicycle exercise testing with spirometry 
(CPX) was used to determine exercise tolerance and oxygen up- 
take. Exercise testing started with a workload of 10 watts, contin- 
uously increasing by 10 watts every minute. Maximum workload 
and peak oxygen consump tion were recorded, and predicted VO2
peak was automatically calculated, considering patients’ gender 
and age. Patient’s individual aerobic–anaerobic threshold and VE/ 
VCO2 slope were determined .
2.7. Statistica l methods 
All data analysis was performed using SigmaPlot™ Software 
(Version 11.0, Systat, Germany). In continuous data, paired t testing cycle. The inspiratory positive airway pressure (IPAP) pressure provides the 
atory pressure is varied between a lower level at the start of expiration (EPAP) and a
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before and after treatment. Analysis of variance with Tukey post 
hoc analysis was used for repeated measures. For nominal vari- 
ables v2 testing was performed. A value of p < 0.05 was considered 
signiﬁcant for all comparisons. Data are presente d as mean ± stan- 
dard deviation (SD) and/or median.
3. Results 
Demograph ic and clinical data are presente d in Table 1. Of the 
45 patients initially included in our study, 38 patients were suc- 
cessfully treated by SOMNO vent CR therapy (Fig. 2). Of the 
remaining seven patients, two patients refused therapy initiation 
and ﬁve patients were without appropriate immediate therapy 
results (AHI > 10/h or >50% of baseline AHI). Within the 
follow-up period a total of 17 patients (37.8%) refused or stopped 
(n = 9) the therapy, were noncomplia nt (n = 3), pending (n = 3), or
were followed up elsewhere (n = 2). Twenty-six patients com- 
pleted the follow-up, with 23 showing appropriate compliance 
with therapy.
In the 23 patients who fulﬁlled the criteria for the ﬁnal assess- 
ment, a sustained reduction was achieved in AHI from baseline to
initial ASV initiation (42.8 ± 17.5/h to 13.3 ± 12.0/h, p < 0.001) to
long-term follow-up after 3.6 ± 1.2 months (9.0 ± 5.9/h; p < 0.001;
Fig. 2). Despite a clear decrease in respiratory events and improve- 
ment in oxygen saturation during the night, a uniform and clini- 
cally relevant improvem ent in sleep quantity and quality could 
not be ascertained (Table 2). In addition, there was no relevant de- 
cline in nocturia frequency (1.94 ± 1.0 per night to 1.89 ± 1.08 per 
night; p = not signiﬁcant).
Regarding HF parameters, NYHA functiona l class improved from 
2.4 ± 0.5 to 2.0 ± 0.4 (p < 0.001) and objective performance during 
CPX testing remarkably improved (Table 3). In addition, daytime 
PaCO2 increased from low-normal values to mid-normal values.Table 1
Demographic and clinical data of all 45 patients (23 compliant patients with complete 
follow-up and 22 patients excluded from further analysis) included in the study.
Parameter All Compliant Excluded patients 
Number of patients (n) 45 (100%) 23 (51.1%) 22 (48.9%)
Age (y) 70.5 ± 9.5 71.1 ± 9.3 69.8 ± 9.8 
Men (n) 41 (91.1%) 20 (87.0%) 21 (95.5%)
BMI (kg/m2) 29.2 ± 5.5 29.2 ± 5.4 29.5 ± 5.4 
Type of heart failure 
Systolic (HF) 20 (44.4%) 8 (34.8%) 12 (54.5%)
Diastolic (HF) 25 (55.6%) 15 (65.2%) 10 (45.5%)
CAD (n) 29 (64.4%) 16 (70%) 13 (54.5%)
Diabetes mellitus (n) 20 (44.4%) 9 (39.1%) 11 (50.0%)
Hypertension (n) 42 (93.3%) 21 (91.3%) 21 (95.5%)
Blood pressure 
systolic (mmHg) 120.3 ± 20.8 118.0 ± 22.5 122.8 ± 19.0 
diastolic (mmHg) 73.5 ± 15.3 71.3 ± 11.9 75.9 ± 18.2 
Heart rate (min1) 70.1 ± 13.4 71.5 ± 10.2 68.7 ± 16.3 
Rhythm
Sinus rhythm (n) 34 (75.6%) 19 (82.6%) 15 (68.2%)
Atrial ﬁbrillation (n) 10 (22.2%) 3 (13.0%) 7 (31.8%)
Pacemaker (n) 1 (2.2%) 1 (4.4%) 0 (0%)
Medication
ACEI/ARB (n) 42 (93.3%) 21 (91.3%) 22 (100%)
b blocker (n) 36 (80.0%) 17 (73.9%) 19 (86.4%)
Diuretics (n) 33 (73.3%) 16 (61.5%) 17 (77.3%)
AldoAnta (n) 20 (44.4%) 10 (43.5%) 10 (45.5%)
Digitalis (n) 7 (15.6%) 2 (8.8%) 5 (22.7%)
Amiodarone (n) 3 (6.7%) 0 (0%) 3 (13.6%)
BMI, body mass index; HF, heart failure; CAD, coronary artery disease; ACEI,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
AldoAnta, aldosterone antagonists.There were no changes in medication within the cohort of the ﬁnal
23 patients.4. Discussion 
In our prospective observational cohort study, we were able to
show beneﬁcial effects of a new Trilevel ASV device on respiratory 
and cardiac parameters in a selected cohort of HF patients with 
combined central and (Fig. 3) mixed sleep apnea. In patients with 
appropriate therapy response during therapy initiation and com- 
pliant to therapy, there was a sustained decrease in nocturna l
apneas and hypopne as with increased oxygen saturations, an
improvem ent in HF symptoms, and objective cardiopulmonar y
performanc e during exercise testing.
Results of the CANPAP trial and its post hoc analysis suggest 
that effective reduction in nocturnal respiratory events is essential 
to enable an improvem ent in cardiac function and the prognosis of
HF patients with SDB and CSR. A residual AHI of 15 per hour seems 
to be inadequate to improve outcome of these HF patients [13,14].
Therefore, for the purpose of our study we aimed to reduce AHI to
fewer than <10 per hour or at least to reduce the number of events 
by 50% within the ﬁrst night. In HF patients with predominant CSR,
ASV has been shown to be more efﬁcient than oxygen, CPAP or bi- 
level positive airway pressure (PAP) within the ﬁrst night of ther- 
apy [16,17]. These superior effects of ASV were conﬁrmed after 
6 months and 12 months by other (Fig. 4) studies using various de- 
vices [18–20]. The therapeuti c efﬁcacy and superiority of ASV vs
CPAP with regard to nocturnal respiratory disturbance s and certain 
cardiac paramete rs have been proven in different clinical studies,
with respect to nocturnal breathing pattern [24], daytime sleepi- 
ness [25], and increase of LVEF after 6 months [18]. Thus, the chal- 
lenge of our study was to treat CSR and coexisting obstructive or
mixed respirato ry events.
The SOMNO vent ASV algorithm is specially designed to treat 
these mixed respiratory events by reacting speciﬁcally to various 
types of respiratory events [26]. In cases of typical CSR, ASV offers 
anticyclic modulate d ventilation to countera ct the waning and 
waxing of respiration during episodes of periodic breathing, while 
deliverin g mandatory ventilator support during central apneas.
Coexisting obstructive events, which are prone to emerge during 
the end of expiration [27,28], are depresse d by an auto regulated 
end–expiratory pressure support to keep airways open. With the 
use of this new algorithm, central, obstructive, or mixed apneic 
events were successfully treated in a single night. Remaining respi- 
ratory events were mainly hypopneas but oxygen saturation 
remarkabl y improved.
Despite altered sleep architecture with reduced sleep efﬁciency
and quality, HF patients do not report SDB-speciﬁc symptom s
[29,30]. Symptoms include more paroxysmal nocturnal dyspnea,
insomnia, and fatigue rather than symptoms associated with day- 
time sleepines s. As in other pilot studies on ASV treatment in HF
patients, we were not able to show notable improvement in sleep 
efﬁciency and quality [31]. In addition, ArI was comparably low at
baseline and did not change with ASV treatment. This ﬁnding is in
close agreement with results of the CANPAP-tri al. Besides a
remarkabl e decrease in AHI, ArI, and sleep architecture did not 
change [32]. Even after successful cardiac transplanta tion, ArI or
sleep structure might not change [33] indicating that arousals 
may exist more or less independently of underlyin g CSR or HF
[32] failure. However, a recent study on acute effects of nocturna l
oxygen or ASV has shown a signiﬁcant decrease within a single 
night of treatment [34]. A ﬁnal answer, if there is one, will probably 
require a large randomized cohort and a longer follow-up, these 
analyses possibly are part of ongoing large-scale randomized con- 
trolled trials (RCTs) like SERVE-HF or ADVENT-HF.
Fig. 2. Study ﬂow chart. 45 heart failure patients with normal (HFNEF) or reduced ejection fraction (HFREF) with moderate to severe central sleep apnea (CSA) or mixed sleep 
apnea (mixSA) were included in our study. Successful therapy initiation was possible in 38 patients (84.4%). Of those, 26 patients (68.4%) completed a follow-up (FU) after 
3.6 ± 1.2 months, with 23 (60.5%) having appropriate compliance with therapy. From enrollment to FU a total of 17 (37.8%) patients refused or stopped therapy or were 
noncompliant, while in ﬁve patients FU was pending or done elsewhere. Data from these patients  were excluded from further analysis.
Table 2
Polysomnographic parameters of 23 compliant patients at baseline and follow-up.
There was a uniform and robust decrease in respiratory events and improvement in
oxygen saturation during the night, in which there were no relevant change in sleep 
quantity and quality.
Parameter Baseline Follow-up P value 
TST (min) 376 ± 58 340.0 ± 65.5 0.082 
WASO (min) 44 ± 37 50.3 ± 41 0.557 
N 1 (%) 12.1 ± 11.6 18.8 ± 15.1 0.075 
N 2 (%) 47.0 ± 13.1 39.0 ± 13.7 0.031 
N 3 (%) 29.2 ± 11.8 28.1 ± 9.6 0.799 
REM (%) 11.7 ± 6.3 12.9 ± 8.1 0.634 
AHI (h1) 42.8 ± 17.5 8.9 ± 5.8 0.001 
AI (h1) 26.6 ± 1.3 0.7 ± 0.9 0.001 
oAI (h1) 10.2 ± 12.9 0.2 ± 0.3 0.001 
cAI h1 10.4 ± 12.0 0.3 ± 0.6 0.001 
mAI (h1) 6.4 ± 8.0 0.2 ± 0.6 0.001 
HI (h1) 16.2 ± 9.5 8.2 ± 5.3 0.003 
Mean SaO 2 (%) 91.9 ± 2.7 93.9 ± 1.7 0.001 
Minimum SaO 2 (%) 79.0 ± 5.7 83.7 ± 8.4 0.019 
Mean O2 desaturation (%) 7.0 ± 3.3 4.2 ± 0.9 0.001 
ArI (h1) 9.4 ± 4.3 7.7 ± 4.8 0.567 
TST, total sleep time; WASO, wake after sleep onset; REM, rapid eye movement 
sleep; AHI, apnea-hypopnea index; AI, apnea index; oAI, obstructive apnea index;
cAI, central apnea index; mAI, mixed apnea index; SaO2, oxygen saturation in pulse 
oximetry; ArI, arousal index.
Table 3
In heart failure patients (New York Heart Association > II) trileve l ASV Therapy 
(SOMNOvent CR) efﬁciently treats nocturnal respiratory disturbances, improves 
clinical heart failure sympto ms, increases objective cardiopulmona ry performance 
and raises daytime pCO 2 to mid-norm al values.
Parameter Baseline Follow-up P value 
NYHA functional class 2.4 ± 0.5 2.0 ± 0.4 0.001 
Workload (watts) 84.3 ± 23.9 92.7 ± 33.8 0.199 
VO2-AT (mmHg) 11.7 ± 2.3 14.2 ± 5.0 0.048 
Peak VO2 (mmHg) 13.6 ± 3.5 15.8 ± 5.8 0.020 
Predicted VO2 peak (%) 61.4 ± 14.8 69.8 ± 23.0 0.026 
VE/VCO 2 (slope) 36.0 ± 4.3 34.2 ± 5.3 0.110 
PaCO 2 (mmHg) 36.4 ± 3.1 37.9 ± 3.8 0.040 
NYHA, New York Heart Association; AT, anaerobic threshold.
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NYHA class, decrease in natriuretic peptide concentrations ,
improvement in LVEF, and enhanced cardiopul monary perfor- 
mance. These studies were performed in HF patients with impaired 
(systolic HF) or preserved (diastolic HF) LVEF and predominant CSR 
without considerabl e obstructive or mixed respirato ry events [35–
37]. Thus, for the purpose of a pilot study investigatin g a new algo- 
rithm based on trilevel ASV, we included patients with systolic and 
diastolic HF but with more complex SDB. In this ﬁrst study, trilevel 
ASV effectively treated respiratory events and improved HF symp- 
toms and performanc e during cardiopulm onary exercise testing.With ASV, NYHA functional class and oxygen uptake at the individ- 
ual aerobic-anaer obic threshold as well as peak oxygen uptake and 
predicted peak oxygen uptake improved by a clinically relevant 
and statistically signiﬁcant magnitude.
Chronic hyperventilation represents a clinical sign of impaired 
respirato ry control in HF patients [6,7,15,3 7,38] . This hyperven tila- 
tion can result in CSR while patient is asleep but can continue dur- 
ing the day while the patient is awake, as documented by a low 
PaCO2 (usually <38 mmHg) [39]. In our study, ASV was able to
countera ct hyperventilati on as documented by a slight but signiﬁ-
cant increase in daytime PaCO 2 and a trend towards a decrease in
VE/VCO2 slope which is an indicator of central CO2-receptor sensi- 
tivity and marker of respirato ry control (in)stability and prognosis 
in HF patients [38,40,41]. Further studies are warranted to conﬁrm
these effects and to analyze if this is a direct effect of ASV treat- 
ment on respiratory control or if stabilized respiration represents 
an indirect effect of improved cardiac and cardiopulmonar y
function.
PAP therapy is not tolerated by every patient [42]. Especiall y HF
patients are sometimes very sensitive to PAP treatment. Thus, ASV 
Fig. 3. Apnea-hypopnea index and central apnea index signiﬁcantly decreased from baseline to adaptive servoventilation therapy initiation and follow-up in patients with 
complete FU and compliant to therapy. (p < 0.05).
Fig. 4. Cardiorespiratory exercise testing results. There was a signiﬁcant increase in
oxygen uptake at the individual anaerobic threshold (AT) and peak oxygen uptake 
(peak VO2) from baseline to follow-up.
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and most comfortable inspiratory pressure support. ASV is pre- 
ferred to all other PAP therapy modalities [16] but still requires a
mask and overcoming resistance to therapy daily, particularly in
patients who do not perceive an immediate subjectiv e beneﬁt. In
our study a total of 20% of patients rejected ASV treatment from 
ﬁrst offer to follow-up after three months. In previous studies 
using a different ASV device, we documented an initial rejection 
rate at therapy initiation of 15.7%, followed by an additional 
17.6% within the ﬁrst six months of therapy. However, until more 
recently and until invasive therapy options (eg, transvenous phre- 
nic nerve stimulation) [43] have shown long-term therapeutic ben- 
eﬁt, ASV treatment represents the gold standard of CSR treatment 
in HF patients.
Finally our clinical study showed that HF patients with con- 
founded types of SDB including central and mixed events may ben- 
eﬁt from trilevel ASV with respect to nocturna l respiratory 
disturbance s, cardiopulm onary performanc e, and clinical symp- 
toms. Further studies are needed to examine if these improve- 
ments result in an increase in quality of life, fewer HF-associated 
hospital admissions, and a positive impact on mortality .5. Limitations 
Our study was designed as an observational pilot study to
investiga te the effects of a new ASV algorithm in HF patients with 
a challenging type of SDB. Positive effects on nocturnal respiratory 
effects have been shown in a highly selected cohort of patients 
with good initial therapy response and adherent to long-term ther- 
apy. Thus, there are a non negligible number of patients without 
appropriate initial therapy response, emphasizing the need for an
RCT. Two large-scal e multicenter RCTs currently are investiga ting 
the effects of ASV on mortality and hospitalization in patients with 
systolic HF. The Treatment of Predominan t Central Sleep Apnoea 
by Adaptive Servo Ventilati on in Patients with Heart Failure 
(Serve-HF) study (ClinicalTrials.gov Identiﬁer: NCT00733343) is
expected to answer this question by 2015. The second RCT (AD-
VENT-HF ) investiga tes the Effects of Adaptive Servo Ventilation 
(ASV) on Survival and Hospital Admission in Heart Failure inde- 
pendent of a predomin ance of central or obstructive respiratory 
events (ClinicalTrials.gov Identiﬁer: NCT01128816). However,
none of these studies are using the device used in our study and 
none are investigatin g the effects on diastolic HF.
6. Conclusion 
In selected HF patients trilevel ASV therapy is able to treat even 
challengi ng SDB with combined central and mixed respiratory 
events. This treatment is associated with an improvem ent in HF
symptom s and in objective cardiopulmonar y performance. The 
possible inﬂuence on quality of life and the prognost ic value of tri- 
level ASV therapy need to be determined in large RCTs. In fact our 
pilot study does not allow generaliz ed conclusio ns but represents a
ﬁrst step towards a better understand ing of these challengi ng pa- 
tients. Finally there is a need for studies investigatin g the role of
SDB in diastolic HF including the effects of SDB treatment in these 
patients.
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